Fluorometholone 0.1% eye drops
Requires a prescription from a doctor or prescriber
A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Fluorometholone
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Fluorometholone
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
8 branded products available
MHRA licensed products
View all licensed products for Fluorometholone on the MHRA register
FML Liquifilm 0.1% ophthalmic suspension
FML Liquifilm 0.1% ophthalmic suspension
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 2 · Randomised trials: 9 · 1975–2026
Showing the 50 most relevant studies, sorted by most relevant.
Xiuwen Zhang, Zhuqing Shen, Hong Sun, et al.
International Ophthalmology, 2023
- Corneal Opacity
- Ocular Hypertension
- Refractive Surgical Procedures
José Pinto-Fraga, A. López-Miguel, M. J. González-García, et al.
Ophthalmology, 2016
- Administration, Topical
- Conjunctiva
- Cornea
Kempen JH, Abashawl A, Mohammed AA, et al.
2026
- Trachoma
- Fluorometholone
- Anti-Inflammatory Agents
Liu AYX, Van Der Meeren SW, Coumou AD, et al.
2026
PurposeThis study evaluated the effects of artificial tears, vitamin A ointment and low-dose steroid drops on chronic irritation and discharge in anophthalmic patients wearing ocular prostheses. It also aimed to identify patient subgroups that may benefit from specific regimens.MethodsThis prospective, crossover randomised trial used a Williams design with 40 ocular prostheses wearing participants aged 16 years or older who experienced chronic discharge or discomfort.Each participant underwent four 2-week intervention periods: artificial tears, vitamin A ointment, low-dose steroids (fluorometholone) and no medication as a control, separated by 2-week washout periods. Visual analogue scale questionnaires assessed discharge and irritation frequency and severity. Data were analysed using linear mixed models with Bonferroni correction for multiple comparisons and subgroup analyses were descriptive.ResultsIn the total group, vitamin A ointment most consistently improved all outcome parameters: irritation frequency (-1.766, 95% CI (-2.857 to -0.675), pConclusionsVitamin A ointment demonstrated the most consistent benefit in anophthalmic patients wearing ocular prostheses, whereas artificial tears and low-dose steroid drops were associated with clinically relevant improvement in a subset of individual patients with chronic irritation and discharge.
Abstract licence: CC BY-NC
John H. Kempen, Redda Tekle‐Haimanot, Lelisa Hunduma, et al.
American Journal of Ophthalmology, 2018
- Anti-Inflammatory Agents
- Fluorometholone
- Intraocular Pressure
Jinsoo Kim, Dong Chul Choi, Seokhyun Bae, et al.
Journal of Ocular Pharmacology and Therapeutics, 2018
- Administration, Topical
- Dexamethasone
- Diclofenac
Hassan Razmjoo, Mohammad Mikaniki, Alireza Peyman, et al.
European Journal of Ophthalmology, 2022
- Eye Diseases
- Photorefractive Keratectomy
- Loteprednol Etabonate
Minjie Chen, Bilian Ke, Jun Zou, et al.
Journal of Clinical Medicine, 2022
José Estevez, Konrad Pesudovs
Ophthalmology, 2017
Khalid F. Tabbara, Soliman A Al-Kharashi
British Journal of Ophthalmology, 1999
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Body Temperature
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
There is no generally accepted explanation for the mechanism of action of ocular corticosteroids.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 855 interactions
Proteins and enzymes this drug interacts with in the body
PMID:27120390 PMID:37478846
Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors .
PMID:28139699
Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling .
PMID:9590696
Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay .
PMID:25775514
Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that carry this drug through the body
ATC D07XB04
ATC D07AB06
ATC S01BA07
ATC S01BB03
ATC C05AA06
ATC D07CB03
ATC S01CB05
ATC S01CA07
ATC D10AA01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Fluorometholone
Additional database identifiers
Drugs Product Database (DPD)
7576
Drugs Product Database (DPD)
7577
ChemSpider
9494
BindingDB
50103631
ZINC
ZINC000118912517
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7978
GenAtlas
NR3C1
GeneCards
NR3C1
GenBank Gene Database
X03225
GenBank Protein Database
31680
Guide to Pharmacology
625
UniProt Accession
GCR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2638
GenAtlas
CYP3A5
GeneCards
CYP3A5
GenBank Gene Database
J04813
GenBank Protein Database
181346
Guide to Pharmacology
1338
UniProt Accession
CP3A5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1540
GenAtlas
SERPINA6
GeneCards
SERPINA6
GenBank Gene Database
J02943
GenBank Protein Database
179971
UniProt Accession
CBG_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q607349), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.